Opioids: Neonatal Abstinence Syndrome/Neonatal Opioid Withdrawal Syndrome
Opioid use has extensive public health implications. In Wisconsin, drug-related deaths involving opioids (per 100,000 population) increased from 5.3 in 2006 to 6.7 in 2015. Cases of neonatal abstinence syndrome (NAS) (per 1000 hospital births) increased from 2.0 in 2006 to 8.7 in 2014. These figures may underestimate the actual numbers of infants affected because if women are not screened and their infants are discharged by day three of life, NAS associated with long-acting opioids, e.g., methadone or buprenorphine, may not be apparent and the infants may not be identified.
This clinical initiative is the first of three focused on improving care for women and infants affected by opioids. The aim of the initiative is to 1) improve identification of infants at risk for Neonatal Abstinence Syndrome (NAS)/Neonatal Opioid Withdrawal Syndrome (NOWS) and 2) standardize care. Future clinical initiatives will address screening women and improving care.
This initiatives are supported by Cooperative Agreement Number DP006359, funded by the Centers for Disease Control and Prevention.
The contents are solely the responsibility of the authors and do not necessarily represent the official views of the Centers for Disease Control and Prevention or the Department of Health and Human Services.
NAS/NOWS Informational Webinar Series
October 31, 2018
WisPQC Informational Webinar for NAS/NOWS Initiative
November 7, 2018
WisPQC Standardized Protocol Webinar for NAS/NOWS Initiative
November 13, 2018
WisPQC Data Collection and Reports Webinar
November 27, 2018
WisPQC Change Package Webinar for NAS/NOWS Initiative
December 6, 2018
WisPQC Eat, Sleep, Console (ESC) Webinar for NAS/NOWS Initiative
December 12, 2018
Learning Collaborative Sessions
January 9, 2019
10:00 a.m.-12:00 p.m.
WisPQC Neonatal Opioid Kick-Off Meeting